Clinical experience of COVID-19 patients: Disease course and treatment features

Aliza Zeidman, Head of Internal Medicine B – Corona B Department, Hasharon Hospital. KKL 7, St Petah Tikva, Israel
2020 The Gazette of Medical Sciences  
The first and only Corona Israeli hospital opened on March 2020 designated to treat positive COVID-19 in-patients solely. We present our clinical experience and outcome on 52 COVID-19 in-patients on Corona B department. Methods: The research cohort included 52 COVID-19 adult Israeli patients. Information on epidemiologic, demographic, clinical, laboratory, imaging and treatments features. Research individuals were categorised into disease severity categories of mild versus moderate and severe
more » ... sease was compared. Results: The mean age among the mild and the moderate-severe disease patients was 57.10 ± 17.69 and 70.07 ± 12.71 years, respectively (p=0.023, 75% had mild disease and the majority were men (55.8%). The most common coexisting comorbidities were hypertension and Diabetes mellitus. The main symptoms were fatigue (73.1%) and cough (63.5%). Laboratory abnormalities included elevated inflammatory markers such as serum ferritin, CRP, D-dimer and Troponin levels. Majority of patients with mild disease had a normal chest x-ray imaging, in contrast to patients with moderate-severe disease (p=0.011). Bilateral pulmonary opacities found in 61.5% of patients with moderate-severe disease, versus 18.2% of patients with mild disease (p=0.001). The patients received varied treatments, including O 2 supplementation, inhalations, High flow nasal oxygen, antibiotics, glucocorticoids, Hydroxychloroquine, Tocilizumab, anticoagulation and physiotherapy. Conclusions: There was difference between patients with mild disease compared to moderate to severe disease in terms of clinical, laboratory and imaging results, course of disease and treatment. Hopefully, our study notions will contribute to the COVID-19 knowledge growing field, and might help understating the disease course and treatments development.
doi:10.46766/thegms.virology.20060302 fatcat:zvnxbkosg5crxmbh2xexag5dma